The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
about
Molecular biology of lung cancer: clinical implicationsNon-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary resultsNew molecularly targeted therapies for lung cancerK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueOne mouse, one patient paradigm: New avatars of personalized cancer therapyPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.CIViC databasePrognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysisA murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerMicroRNA signatures in human cancersKRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerA novel classification of lung cancer into molecular subtypesPredictive and prognostic molecular markers for cancer medicineImage-based compound profiling reveals a dual inhibitor of tyrosine kinase and microtubule polymerizationA pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerRole of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancerMolecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing.A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Molecular pathways and therapeutic targets in lung cancerKRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Prognostic factors in resected lung carcinomas.EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases.Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients.Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASTargeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.Lung cancer in never smokers: molecular profiles and therapeutic implications.Ras in cancer and developmental diseasesImplementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemPredictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
P2860
Q24610335-2D5AACE8-611D-4759-B282-4BFC09C65FE7Q24630546-469BC12F-E31F-4195-840E-4ED5C2F68EE5Q24680988-51EC2C81-D2C3-44B8-9F2D-A6352FB21424Q26829425-82BCEFAE-6DF8-435F-AF99-0C58FAD373F0Q27023342-7B2F7C4B-0A47-4358-819E-1B5CCEC8E7F9Q27313799-B17D728D-637B-4A61-990C-C0A7BDD96548Q27612411-B8E62D95-44D1-4E26-B46F-283B0A92B30EQ27692669-93944E6E-270A-4496-BB01-196DDBF8833AQ27851728-E18CB482-E085-4106-B0D7-FF3868953679Q27851860-E2BC4272-7A6D-4B50-B989-880B6F715728Q27853180-0ECDF236-426E-40C1-A8A0-9BDBEDF6D9BDQ27860962-720D7964-7730-4495-85CC-D1B5111E36F8Q28077570-C23E2997-A339-4317-AB11-BF3F152F1239Q28083446-30B93A28-CDC3-4749-B4E0-CF9BF1D90380Q28303718-AEB216DB-CEFA-4A29-9E77-096F99636B48Q28396304-309596BE-F066-4619-968A-EC4A8D829DF8Q28731874-0583BAA3-8347-4D0E-92A9-E504097C67B0Q28743108-310FB6CC-54B3-4961-ABF3-AF85469D8436Q28834113-E0A86F72-5EFA-462C-9329-503CBB0056A0Q30539299-21E8FC8C-62F6-42B3-9F82-FCD5A488FD17Q33576845-05DD9BAF-408F-415D-854A-0EC00075624AQ33609045-AF16BC7F-A284-4063-B105-B409C633366FQ33621880-94659CA2-29FA-4C87-A223-ADFDDF9D3364Q33633715-99128DCA-558F-4A0F-A00F-8C3AFF13F67BQ33634165-6137FEDC-B9BD-4C4B-83AC-F03FFDEA6E54Q33648808-F9957B2B-3085-4F2D-8717-6FB4A3809D32Q33688872-E4D4F8F7-F811-4BE5-8B4A-AF8863BD395AQ33690682-797ABD2B-15E6-4879-B1EB-3F4243C6D09BQ33697964-2B906F30-5C4B-4EBF-BCE2-602D0D40436AQ33814702-70371DCD-2EBD-4B3D-9305-7F5521F16A70Q33868092-1DFC0AE9-BD76-48CF-8AD5-5931BDBCDD6CQ34023414-11901B7F-F170-489E-A80B-C896053CE55DQ34158153-B822041B-8BBB-4DC7-8970-5918F3FEED15Q34165233-25C6EFBA-49B7-48FF-9E8B-AA28114DE23EQ34177155-C2E5CB77-F123-4F60-9A07-1AEA8369826DQ34202697-5BB50076-7463-4A8A-85AA-5D5FB55F8DDFQ34404229-13522E1D-1911-4CFB-B743-347B0D281022Q34608597-21A1388C-6F34-4F99-AE83-B4CC02153B06Q34620545-A809119F-E66C-4BC8-8F23-C2092C406F30Q34701196-2C7E3B75-8F34-47D2-9B0D-90D306589669
P2860
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The role of RAS oncogene in su ...... literature with meta-analysis
@ast
The role of RAS oncogene in su ...... literature with meta-analysis
@en
The role of RAS oncogene in su ...... literature with meta-analysis
@nl
type
label
The role of RAS oncogene in su ...... literature with meta-analysis
@ast
The role of RAS oncogene in su ...... literature with meta-analysis
@en
The role of RAS oncogene in su ...... literature with meta-analysis
@nl
prefLabel
The role of RAS oncogene in su ...... literature with meta-analysis
@ast
The role of RAS oncogene in su ...... literature with meta-analysis
@en
The role of RAS oncogene in su ...... literature with meta-analysis
@nl
P2093
P2860
P31
P921
P3181
P356
P1476
The role of RAS oncogene in su ...... literature with meta-analysis
@en
P2093
J-J Lafitte
J-P Sculier
M Paesmans
P Lothaire
P2860
P2888
P3181
P356
10.1038/SJ.BJC.6602258
P407
P577
2005-01-17T00:00:00Z
P5875
P6179
1041396541